Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px
Product › Details

Imfinzi®

Products Next higher product group durvalumab (MEDI4736, anti-PD-L1 antibody)
Period Status 2017-05-01 registration start
Organisation Organisation MedImmune (biologics division of AstraZeneca)
  Group AstraZeneca (Group)
Document Source AstraZeneca plc. (5/1/17). "Press Release: AstraZeneca’s Imfinzi (durvalumab) Receives US FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer".
     

   
Record changed: 2018-04-28

Advertisement

Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for Imfinzi®


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top